ALK-Abello AS - Company Profile
Powered by 
All the data and insights you need on ALK-Abello AS in one report.
$295
- Save hours of research time and resources with
our up-to-date ALK-Abello AS Strategy Report
- Understand ALK-Abello AS position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
ALK-Abello AS (ALK), a subsidiary of The Lundbeck Foundation, discovers, develops, and commercializes immunotherapies to treat and prevent allergies. The company's allergy immunotherapy product portfolio includes tablets, sublingual or drop-based vaccines, subcutaneous vaccines, and adrenaline auto-injectors to treat severe allergic reactions in emergencies (anaphylaxis). ALK’s research and development pipeline products include sublingual immunotherapy tablets for addressing ragweed, house dust mite, and tree pollen allergy. The company’s products target allergies caused by grass, tree, ragweed, house dust mite, Japanese cedar, and venom. The company has subsidiaries in Europe, North America and Asia-Pacific. ALK is headquartered in Horsholm, Denmark.
Headquarters
Denmark
Address
Boege Alle 6-8, Hoersholm, 2970
Website
www.alk.net
Telephone
45 45 747576
No of Employees
2,824
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ALK B (CPH)
Revenue (2022)
$700.2M
6.9%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
45.1%
(2022 vs 2021)
Market Cap*
$3.6B
Net Profit Margin (2022)
XYZ
35.5%
(2022 vs 2021)
* As of and is in US$
ALK-Abello AS premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Tablets | Acarizax |
| Sublingual Vaccines | Grastek |
| Subcutaneous Vaccines | Grazax |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Asset Purchase | In January, the company acquired the business assets of AllerQuest. |
| 2023 | Contracts/Agreements | In December, the company extended its partnership and entered into an additional license agreement, with Torii in Japan to develop, market and distribute immunotherapy tablets. |
| 2023 | Contracts/Agreements | In June, ALK Life Science Solutions entered into an agreement with Galenova for the distribution of high-quality glass vials in Canada. |
Competitor Comparison
| Key Parameters | ALK-Abello AS | Allergy Therapeutics Plc | Allergopharma GmbH & Co KG | Biomay AG | Stallergenes Greer Ltd |
|---|---|---|---|---|---|
| Headquarters | Denmark | United Kingdom | Germany | Austria | United Kingdom |
| City | Hoersholm | Worthing | Reinbek | Vienna | London |
| State/Province | - | England | Schleswig-Holstein | Wien | England |
| No. of Employees | 2,824 | 635 | - | - | 1,045 |
| Entity Type | Public | Public | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Anders Hedegaard | Chairman | Executive Board | 2020 | 64 |
| Peter Halling | President; Chief Executive Officer | Senior Management | 2024 | 47 |
| Claus Steensen Solje | Executive Vice President; Chief Financial Officer | Senior Management | 2023 | 52 |
| Per Plotnikof | Head - Investor Relations | Senior Management | - | - |
| Henriette Mersebach | Managing Director - Research and Development; Executive Vice President - Research and Development | Senior Management | 2023 | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward